Peregrine Pharma New (PPHM) 0.36 $PPHM Peregrine to

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:14 AM

Peregrine Pharma New (PPHM) 0.36 $PPHM

Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016
GlobeNewswire - Thu Sep 01, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report financial results for the first quarter of fiscal year 2017 ended July 31, 2016 on September 8, 2016 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the first quarter and review recent corporate developments.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)

Avid Bioservices to Participate in Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
GlobeNewswire - Tue Aug 09, 7:05AM CDT
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), today announced that the company will have a significant presence at Cambridge Healthtech Institute's (CHI) 8 Annual The Bioprocessing Summit, being held August 15-19, 2016 in Boston, MA. The company's vice president of process sciences, Pete Gagnon, will make a presentation centered on the role of protein A in biomanufacturing and will serve as one of three expert participants for a panel discussion on technology advancements that can assist biological drug manufacturers in achieving optimal viral clearance during the performance of downstream purification processes.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.94 (+0.28), PACB: 8.30 (-0.03), AVXL: 3.03 (-0.03), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (Nasdaq

PHM) (Nasdaq

PHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"

.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Penny Stocks to Watch: Top Small Cap Stocks Investors Are Considering on Wednesday May 11
ACCESSWIRE - Wed May 11, 11:54AM CDT
MIAMI, FL / ACCESSWIRE / May 11, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. PPHM, MGT, SAKL, and GOGY have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
PPHM: 0.36 (unch)

Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 44.90 (+0.35), IMGN: 2.80 (-0.01), PPHM: 0.36 (unch), SRNE: 6.76 (+0.10), CELG: 106.37 (-0.37)

Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.36 (unch)

Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 32.60 (-0.21), HZNP: 18.62 (-0.18), PPHM: 0.36 (unch), SNY: 38.41 (-0.06)

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 1.91 (-0.06), PIRS: 1.61 (+0.01), AST: 2.82 (+0.03), PPHM: 0.36 (unch)

Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.36 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Decibel's Bold Move to Trade on OTCQX: A New Era

Decibel Sets Sail on the OTCQX Best Market Right off the bat, we're talking about Decibel Cannabis Company Inc. making waves by jumping from the OTCQB to the more reputable OTCQX Best Market. If this doesn’t make you sit up and take notice, I don’t know what will. The ticker OTCQX:DBCCF is now on a stage where it can potentially woo more U.S. investors, and given the...

Cemig and Huawei's Bold Network Leap: Power Up

By Ryan Hughes Updated Nov 13, 2026 Category News Views 120

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

Hebrew Learning Made Simple: Expert's Structured Guide

Cracking the Hebrew Code: A Balanced Guide Ever tried staring down a new language script and felt like you were on a sinking ship? That’s where a lot of folks starting off with Hebrew reading find themselves. It's no sunny stroll through a Greek alphabet park—Hebrew's a whole different ballgame. But Diana Yacobi from Sarah & David’s Read Hebrew Now offers a roadmap...

Duke Energy's Cooling Tips Amid Florida Cold Front

Weather Whiplash in Florida Prompts Energy Tips Florida's residents are in for a gust of chilly air as a cold front sweeps across the state, sending temperatures plummeting from the balmy 80s to brisk 30s and 40s in northern pockets. Central Florida ain't missing out on the chill either, expecting to dip a good dozen degrees below its usual seasonal warmth. Heads up,...

Samuel Oschin Center Opens, Promising Wonder

By Evelyn Baker Updated Nov 13, 2026 Category News Views 107

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Data Centers: More Power-Hungry Than Thirsty

By Addison Perry Updated Nov 13, 2026 Category News Views 147

Data Centers: Not Quite the Water Guzzlers We Feared Hold onto your hats, because the latest intel on data centers is changing the game, or at least forcing a closer look at what seems like a done deal. The big reveal? It's not the water, folks—it’s the juice. While everyone frets about water, electricity is the silent giant you’ve got to wrangle. Water vs....

Lavazza 2027 Calendar: Moments of Pleasure Worldwide

Capturing Fleeting Joy Through the Lens In 2027, Lavazza sets the stage for an evocative exploration of human pleasure through its iconic calendar. Teaming up with photographers Jim Goldberg, Alex Majoli, and Paolo Pellegrin, the project spans three vibrant cities: New York, Lisbon, and Hong Kong. These masters of the lens invite us to pause and appreciate the understated...

Immunic, Inc. Steams Ahead: Phase 3 Trials Hinge on MS Data

A Pivotal Moment for Immunic We’re staring down a critical December for Immunic, Inc. as they trot out top-line data for their Phase 3 ENSURE trials aimed at relapsing multiple sclerosis (MS). Now, I’m all ears wondering if those trials can hold water — success could morph them from a tinkering biotech into a commercial giant. For market vultures like us,...

JardogsHealth Taps Industry Titans for Growth Council

JardogsHealth: A New Chapter with Strategic Insights You've got to admire when a company rounds up a top-tier brain trust. Such is the case with JardogsHealth, the healthcare AI outfit nestled in Hillsboro, Illinois, as they align their future alongside heavyweights who’ve maneuvered through multiple industries and come out thriving. Their brand-new council includes...